Brief: OncoCyte’s Determaio Clinical Test Predicts Response To Immunotherapy In Triple Negative Breast Cancer
09/12/2021 23:26
Dec 9 (Reuters) - OncoCyte Corp OCX.O :
* SPOTLIGHT POSTER PRESENTATION AT SAN ANTONIO BREAST CANCER
SYMPOSIUM SABCS 2021 SHOWS ONCOCYTE’S DETERMAIO™ CLINICAL TEST
PREDICTS RESPONSE TO IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST
CANCER
Source text for Eikon: ID:nGNX2vfW5F
Further company coverage: OCX.O
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission